BioTrinity 2018: Bullish M&A And IPO Outlook; Spotlight On Eyevensys, Rexgenero
Executive Summary
Industry experts, investors and start-ups from across the pharma, biotech and medtech sectors gathered at the recent annual BioTrinity conference held in London to hear how the capital-raising climate is looking rosy for 2018, and to explore partnering and investment opportunities. Medtech Insight reports on predicted trends in health care and highlights two companies, Eyevensys and Rexgenero, that were presenting at the conference.